Do new protease inhibitors offer improved clinical effectiveness? Issues of PI potency and efficacyYOUNG, Benjamin; MARKOWITZ, Martin.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 35, pp 3-12, issn 1525-4135, 10 p., SUP1Conference Paper

In Vitro Characterization of Multidrug-Resistant HIV-1 Isolates From a Recently Infected Patient Associated With Dual Tropism and Rapid Disease ProgressionMOHRI, Hiroshi; MARKOWITZ, Martin.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 48, Num 5, pp 511-521, issn 1525-4135, 11 p.Article

Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspectiveLOUIE, Michael; MARKOWITZ, Martin.Antiviral research. 2002, Vol 55, Num 1, pp 15-25, issn 0166-3542Article

Lopinavir. CommentariesHURST, Miriam; FAULDS, Diana; MARKOWITZ, Martin et al.Drugs (Basel). 2000, Vol 60, Num 6, pp 1371-1381, issn 0012-6667Article

The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1-Infected IndividualsHOGAN, Christine M; DEGRUTTOLA, Victor; KALLUNGAL, Beatrice et al.The Journal of infectious diseases. 2012, Vol 205, Num 1, pp 87-96, issn 0022-1899, 10 p.Article

Transmitted Drug Resistance and Phylogenetic Relationships Among Acute and Early HIV-1―Infected Individuals in New York CityCASTOR, Delivette; LOW, Andrea; EVERING, Teresa et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 1-8, issn 1525-4135, 8 p.Article

Drug-Susceptible HIV-1 Infection Despite Intermittent Fixed-Dose Combination Tenofovir/Emtricitabine as Prophylaxis Is Associated With Low-Level Viremia, Delayed Seroconversion, and an Attenuated Clinical CoursePRADA, Nicole; DAVIS, Brandi; JEAN-PIERRE, Patrick et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 2, pp 117-122, issn 1525-4135, 6 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infectionMEHANDRU, Saurabh; VCELAR, Brigitta; CARRINGTON, Mary et al.Journal of virology. 2007, Vol 81, Num 20, pp 11016-11031, issn 0022-538X, 16 p.Article

Plasma HiV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens : ACTG A5166s. CommentaryMARKOWITZ, Martin; PERELSON, Alan S; MEYER, William A et al.The Journal of infectious diseases. 2007, Vol 195, Num 8, issn 0022-1899, 1087-1088,1169-1176 [10 p.]Article

Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infectionDI MASCIO, Michele; MARKOWITZ, Martin; LOUIE, Michael et al.Journal of virology. 2004, Vol 78, Num 19, pp 10566-10573, issn 0022-538X, 8 p.Article

Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infectionSMITH, Don; BERREY, M. Michelle; COREY, Lawrence et al.The Journal of infectious diseases. 2000, Vol 182, Num 3, pp 950-954, issn 0022-1899Article

Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)GOTUZZO, Eduardo; MARKOWITZ, Martin; TEPPLER, Hedy et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 73-77, issn 1525-4135, 5 p.Article

Colonization and Subsequent Skin and Soft Tissue Infection Due to Methicillin-Resistant Staphylococcus aureus in a Cohort of Otherwise Healthy Adults Infected with HIV Type 1SHET, Anita; MATHEMA, Barun; KREISWIRTH, Barry N et al.The Journal of infectious diseases. 2009, Vol 200, Num 1, pp 88-93, issn 0022-1899, 6 p.Article

Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionBROWN, Andrew J; FROST, Simon D. W; ROUTY, Jean-Pierre et al.Journal of virology. 2004, Vol 78, Num 5, pp 2242-2246, issn 0022-538X, 5 p.Article

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individualsLOUIE, Michael; HOGAN, Christine; PERELSON, Alan S et al.AIDS (London). 2003, Vol 17, Num 8, pp 1151-1156, issn 0269-9370, 6 p.Article

Determining the relative efficacy of highly active antiretroviral therapyLOUIE, Michael; HOGAN, Christine; HO, David D et al.The Journal of infectious diseases. 2003, Vol 187, Num 6, pp 896-900, issn 0022-1899, 5 p.Article

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individualsSIMON, Viviana; VANDERHOEVEN, Jeroen; HURLEY, Arlene et al.AIDS (London). 2002, Vol 16, Num 11, pp 1511-1519, issn 0269-9370Article

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapyMITTLER, John; ESSUNGER, Paulina; YUEN, Geoffrey J et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 5, pp 1438-1443, issn 0066-4804Article

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialPOZNIAK, Anton; MARKOWITZ, Martin; GARNER, Will et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 7, pp 590-599, issn 1473-3099, 10 p.Article

Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication CapacityBROCKMAN, Mark A; CHOPERA, Denis R; CHEUNG, Peter K et al.Journal of virology. 2012, Vol 86, Num 12, pp 6913-6923, issn 0022-538X, 11 p.Article

Identifying the Early Post-HIV Antibody Seroconversion PeriodHECHT, Frederick M; WELLMAN, Robert; HOLTE, Sarah et al.The Journal of infectious diseases. 2011, Vol 204, Num 4, pp 526-533, issn 0022-1899, 8 p.Article

Transmission and Long-Term Stability of Compensated CD8 Escape MutationsSCHNEIDEWIND, Arne; BRUMME, Zabrina L; ONIANGUE-NDZA, Cesar et al.Journal of virology. 2009, Vol 83, Num 8, pp 3993-3997, issn 0022-538X, 5 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety dataVCELAR, Brigitta; STIEGLER, Gabriela; KATINGER, Hermann et al.AIDS (London). 2007, Vol 21, Num 16, pp 2161-2170, issn 0269-9370, 10 p.Article